Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Frontal fibrosing alopecia Indication Strategy Report 2026: PPAR-gamma, Trials and Deals
24 July 2026
2026 Frontal fibrosing alopecia strategy: epidemiology, PPAR-gamma biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Lichen planopilaris Indication Strategy Report 2026: JAK1, Trials and Deals
24 July 2026
2026 Lichen planopilaris strategy: epidemiology, JAK1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Necrobiosis lipoidica Indication Strategy Report 2026: TNF, Trials and Deals
24 July 2026
2026 Necrobiosis lipoidica strategy: epidemiology, TNF biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Granuloma annulare Indication Strategy Report 2026: JAK1, Trials and Deals
24 July 2026
2026 Granuloma annulare strategy: epidemiology, JAK1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
NCT07553988 RS-113 Metastatic castration-resistant prostate cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07553988 clinical trial report covering RS-113, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2031260060 Naldemedine Tosylate Diarrhea Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
JPRN-jRCT2031260060 clinical trial report covering Naldemedine Tosylate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07554898 Orelabrutinib Marginal Zone B-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07554898 clinical trial report covering Orelabrutinib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07554521 Tislelizumab stomach adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07554521 clinical trial report covering Tislelizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600123587 Albumin-Bound Paclitaxel Locally Advanced Cervical Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
ChiCTR2600123587 clinical trial report covering Albumin-Bound Paclitaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07553442 Zilebesiran Hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07553442 clinical trial report covering Zilebesiran, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600123561 Nicotinamide riboside/Pterostilbene Adult Acute Myeloblastic Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
ChiCTR2600123561 clinical trial report covering Nicotinamide riboside/Pterostilbene, Phase 2, endpoints, sponsor, geography, readout timing and development wh
Latest Hotspot
8 min read
NCT07553338 Leronlimab Alzheimer Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07553338 clinical trial report covering Leronlimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.